Metastatic Head And Neck Squamous Cell Carcinoma clinical trials

Explore recruiting metastatic head and neck squamous cell carcinoma clinical trials.

Recruiting metastatic head and neck squamous cell carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Head And Neck Squamous Cell Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2/3, Randomized, Double-Blind, Controlled Study of XL092 in Combination With Pembrolizumab vs Pembrolizumab in the First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Slovakia, France, Romania, Greece, Poland, Bulgaria +7 more

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase II, Multicenter, Randomized Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (ERBIOTAX)

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Carboplatin + Paclitaxel + Cetuximab (PCC) after failure of first line Immune checkpoint inhibitor with or without chemotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck: CARPACCIO (CARboplatin PAClitaxel Cetuximab IO immuno-oncology)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) (LEAP-009)

Norway, Denmark, Portugal, Romania, Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Germany, Italy, Hungary, Spain, Belgium, Poland +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

France, Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Metastatic Head And Neck Squamous Cell Carcinoma trials by city

Metastatic Head And Neck Squamous Cell Carcinoma in Toronto Metastatic Head And Neck Squamous Cell Carcinoma in Vancouver Metastatic Head And Neck Squamous Cell Carcinoma in Montreal Metastatic Head And Neck Squamous Cell Carcinoma in Calgary Metastatic Head And Neck Squamous Cell Carcinoma in Edmonton Metastatic Head And Neck Squamous Cell Carcinoma in Ottawa Metastatic Head And Neck Squamous Cell Carcinoma in Winnipeg Metastatic Head And Neck Squamous Cell Carcinoma in Quebec City Metastatic Head And Neck Squamous Cell Carcinoma in Hamilton Metastatic Head And Neck Squamous Cell Carcinoma in Kitchener Metastatic Head And Neck Squamous Cell Carcinoma in London Metastatic Head And Neck Squamous Cell Carcinoma in Halifax Metastatic Head And Neck Squamous Cell Carcinoma in New York Metastatic Head And Neck Squamous Cell Carcinoma in Los Angeles Metastatic Head And Neck Squamous Cell Carcinoma in Chicago Metastatic Head And Neck Squamous Cell Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease